The mission of the biostatistics shared resource (BSR) is to serve as a focal point for University of Virginia Cancer Center (UVACC) members to obtain assistance in the design, management and analysis of their studies. The services provided by this resource include: 1) Biostatistical collaboration and consultation in the design of clinical trials, observational studies and laboratory studies. An appropriate statistical design is necessary if the research is to be successful in fulfilling the scientific objectives. 2) Statistical expertise in data analysis. The specific methods employed depend on the randomization or sampling design of the particular project and on the scale (binary, ordered categorical, or continuous) of the outcome variable being investigated. Statistical data analyses are performed using both packaged and special purpose computer programs. 3) Scientific review, quality control, and data and safety study monitoring for clinical trials. Involvement throughout the entire process is important to ensure that valid designs are planned as well as followed. 4) Education; through formal and informal seminars, courses and lectures. Education defines the academic environment for which all members participate. 5) Development of statistical methodology, computer programs and infrastructure necessary for meeting the scientific objectives of specific research studies. Advances in research can require the development of new statistical methodologies to achieve the research goals. The BSR enriches research at the UVACC by providing high quality design and analyses for basic, clinical and translational studies and unique expertise in novel designs in early phase trials. The BSR provides statistical knowledge in all phases of clinical research, including scientific and safety review, data quality, and monitoring of on-going trials. Through its educational efforts, the BSR promotes an understanding of statistical principles that enhances research efforts in the UVACC. We have increased the breadth of our collaborative skills to include new areas of expertise including joint modeling of longitudinal assessments and time-to-event endpoints, analyses to assess synergy in pre-clinical studies, and methods for tumor outgrowth studies while augmenting our core expertise in early phase trial design.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-30
Application #
10091435
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-09-16
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
30
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications